Literature DB >> 19034577

Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.

Xiaolong Lee1, Ming Gao, Yifeng Ji, Yang Yu, Ying Feng, Yigong Li, Yan Zhang, Wenyuan Cheng, Wenchuan Zhao.   

Abstract

Papillary thyroid cancers often occur as microcarcinoma. Some papillary thyroid microcarcinoma (PTMC) have been considered to be high aggressive according to advanced disease stages, extrathyroidal extension, and severe cervical lymph node metastasis. Although several factors are thought to predict the occurrence of aggressiveness from PTMCs, the origin of aggressiveness has been rarely studied. To answer this question, the correlation between BRAF(V600E) mutation and high aggressive PTMCs was investigated. The clinicopathological characteristic of totally 64 cases of PTMCs was investigated and the BRAF(V600E) mutational status of them was identified. BRAF(V600E) mutation was exclusively detected in PTMCs (37.5%). The data provided no correlation between the occurrence of BRAF(V600E) mutations and clinicopathological parameters, such as sex, age, and tumor-like lesions combination. The prevalence of BRAF(V600E) mutation of PTMCs with high aggressiveness (advanced disease stages, extrathyroidal extension, and nodal metastasis) was significantly higher (p < 0.05) than that of PTMCs without aggressive behavior. The BRAF(V600E) mutated PTMCs exhibited signs of higher aggressiveness than PTMCs without the mutation. BRAF(V600E) mutation may be a marker of high aggressiveness in PTMCs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19034577     DOI: 10.1245/s10434-008-0233-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  51 in total

1.  Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation.

Authors:  Thomas J Musholt; Sonja Schönefeld; Christina H Schwarz; Felix M Watzka; Petra B Musholt; Christian Fottner; Matthias M Weber; Erik Springer; Arno Schad
Journal:  Langenbecks Arch Surg       Date:  2010-07-18       Impact factor: 3.445

Review 2.  Molecular markers in well-differentiated thyroid cancer.

Authors:  Anil K D'Cruz; Richa Vaish; Abhishek Vaidya; Iain J Nixon; Michelle D Williams; Vincent Vander Poorten; Fernando López; Peter Angelos; Ashok R Shaha; Avi Khafif; Alena Skalova; Alessandra Rinaldo; Jennifer L Hunt; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-04-06       Impact factor: 2.503

3.  A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma.

Authors:  Leo A Niemeier; Haruko Kuffner Akatsu; Chi Song; Sally E Carty; Steven P Hodak; Linwah Yip; Robert L Ferris; George C Tseng; Raja R Seethala; Shane O Lebeau; Michael T Stang; Christopher Coyne; Jonas T Johnson; Andrew F Stewart; Yuri E Nikiforov
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

Review 4.  Molecular analysis of thyroid tumors.

Authors:  Feriyl Bhaijee; Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2011-09       Impact factor: 3.943

5.  The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer.

Authors:  Shan Muhammad; Zheng Jiang; Zheng Liu; Kavanjit Kaur; Xishan Wang
Journal:  J Gastrointest Oncol       Date:  2013-03

6.  Relationship Between 18F-fluorodeoxyglucose Accumulation and the BRAF V600E Mutation in Papillary Thyroid Cancer.

Authors:  Jae Won Chang; Ki Wan Park; Jae Hyung Heo; Seung-Nam Jung; Lihua Liu; Sung Min Kim; In Sun Kwon; Bon Seok Koo
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

Review 7.  Molecular genetics of thyroid cancer.

Authors:  Maha Rebaї; Ahmed Rebaї
Journal:  Genet Res (Camb)       Date:  2016-05-13       Impact factor: 1.588

8.  Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades.

Authors:  Bo Youn Cho; Hoon Sung Choi; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; Kyung Won Kim; Ka Hee Yi; June-Key Chung; Yeo-Kyu Youn; Nam Han Cho; Do Joon Park; Chang-Soon Koh
Journal:  Thyroid       Date:  2013-06-21       Impact factor: 6.568

9.  Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?

Authors:  Kathleen C Lee; Carol Li; Eric B Schneider; Yongchun Wang; Helina Somervell; Matthew Krafft; Christopher B Umbricht; Martha A Zeiger
Journal:  Surgery       Date:  2012-10-11       Impact factor: 3.982

Review 10.  Prognostic utility of BRAF mutation in papillary thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Mol Cell Endocrinol       Date:  2009-10-31       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.